{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:43:07Z","timestamp":1791819787653,"version":"4.3.4"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.addr.2020.08.011","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:29:23Z","timestamp":1598660963000},"page":"176-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Targeting and therapeutic peptide-based strategies for polycystic kidney disease"],"prefix":"10.1016","volume":"161-162","author":[{"given":"Jonathan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmalya","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2020.08.011_bb0005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/febs.15088","article-title":"Identification and classification of epithelial cells in nephron segments by actin cytoskeleton patterns","volume":"287","author":"Kumaran","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.addr.2020.08.011_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis. (Basel)"},{"key":"10.1016\/j.addr.2020.08.011_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5500\/wjt.v2.i4.51","article-title":"Current state of renal transplant immunosuppression: present and future","volume":"2","author":"Kalluri","year":"2012","journal-title":"World J. Transplant."},{"key":"10.1016\/j.addr.2020.08.011_bb0025","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0030","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1503\/cmaj.080351","article-title":"Guidelines for the management of chronic kidney disease","volume":"179","author":"Levin","year":"2008","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.addr.2020.08.011_bb0035","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17109.1","article-title":"Recent advances in the clinical management of autosomal dominant polycystic kidney disease","volume":"8","author":"Torra","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.addr.2020.08.011_bb0040","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group","volume":"5","author":"Klahr","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0045","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","article-title":"Management of autosomal-dominant polycystic kidney disease\u2014state-of-the-art","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.addr.2020.08.011_bb0050","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.krcp.2012.07.002","article-title":"Mammalian target of rapamycin inhibition in polycystic kidney disease: from bench to bedside","volume":"31","author":"Kim","year":"2012","journal-title":"Kidney Res. Clin. Pract."},{"key":"10.1016\/j.addr.2020.08.011_bb0060","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.08.011_bb0065","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ckj\/sfy089","article-title":"Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease","volume":"11","author":"Weimbs","year":"2018","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.addr.2020.08.011_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJNRD.S125942","article-title":"Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations","volume":"11","author":"Sans-Atxer","year":"2018","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"10.1016\/j.addr.2020.08.011_bb0075","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0080","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.08.011_bb0085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MNH.0000000000000333","article-title":"Therapeutic microRNAs in polycystic kidney disease","volume":"26","author":"Yheskel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.addr.2020.08.011_bb0090","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR gene editing in the kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.addr.2020.08.011_bb0095","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2342187","article-title":"Unraveling the effect of immunogenicity on the PK\/PD, efficacy, and safety of therapeutic proteins","volume":"2016","author":"Smith","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17425255.2017.1292251","article-title":"Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics\u2013small molecule drug interactions","volume":"13","author":"Mallick","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2020.08.011_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/molecules24020351","article-title":"Peptide-based drug-delivery systems in biotechnological applications: recent advances and perspectives","volume":"24","author":"Tesauro","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2020.08.011_bb0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/pj.2012.215","article-title":"Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors","volume":"45","author":"Accardo","year":"2013","journal-title":"Polym. J."},{"key":"10.1016\/j.addr.2020.08.011_bb0115","first-page":"92","article-title":"Peptide-based targeting of immunosuppressive cells in cancer","volume":"5","author":"Trac","year":"2020","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2020.08.011_bb0120","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2020.08.011_bb0125","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jphp.12810","article-title":"Immunogenicity assessment during the development of protein therapeutics","volume":"70","author":"Rosenberg","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2020.08.011_bb0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications","author":"Potter","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.addr.2020.08.011_bb0135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.08.011_bb0140","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.addr.2020.08.011_bb0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1210\/jc.2010-1587","article-title":"Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men","volume":"96","author":"Stanley","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2020.08.011_bb0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1208\/s12248-010-9234-9","article-title":"Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2020.08.011_bb0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2125.2004.02175.x","article-title":"Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients","volume":"58","author":"Agers\u00f8","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2020.08.011_bb0160","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1039\/C9TB01918A","article-title":"Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis","volume":"7","author":"Chin","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2020.08.011_bb0165","first-page":"281","article-title":"Theranostic nanoparticles for tracking and monitoring disease state","volume":"23","author":"Zavaleta","year":"2017","journal-title":"SLAS Technol. Translat. Life Sci. Innov."},{"key":"10.1016\/j.addr.2020.08.011_bb0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.apsb.2013.12.005","article-title":"Kidney\u2013targeted drug delivery systems","volume":"4","author":"Zhou","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2020.08.011_bb0175","first-page":"S266","article-title":"Sun-159 oral nanocapsule formulation for polycystic kidney disease","volume":"5","author":"Wang","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.addr.2020.08.011_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-41199-1_1","article-title":"Therapeutic potential of small molecules and engineered proteins","volume":"219","author":"Gurevich","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.addr.2020.08.011_bb0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2020.08.011_bb0190","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1681\/ASN.2017010013","article-title":"Targeting Anti-TGF-\u03b2 therapy to fibrotic kidneys with a dual specificity antibody approach","volume":"28","author":"McGaraughty","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0195","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1039\/C7BM00271H","article-title":"Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease","volume":"5","author":"Wang","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0200","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.addr.2017.12.019","article-title":"Targeting renal fibrosis: Mechanisms and drug delivery systems","volume":"129","author":"Nastase","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.011_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178943","article-title":"Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum","volume":"12","author":"B\u00f6ttger","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.08.011_bb0210","first-page":"23","article-title":"Regulation of kidney function and metabolism: a question of supply and demand","volume":"118","author":"Blantz","year":"2007","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.addr.2020.08.011_bb0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1083\/jcb.201410017","article-title":"Review series: the cell biology of renal filtration","volume":"209","author":"Scott","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0220","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/j.2040-4603.2013.tb00514.x","article-title":"Proximal nephron","volume":"3","author":"Zhuo","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00467-012-2221-x","article-title":"Cystic kidney diseases: many ways to form a cyst","volume":"28","author":"Loftus","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000491022","article-title":"A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression","volume":"48","author":"Magistroni","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0240","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2215\/CJN.03960318","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease","volume":"13","author":"Chebib","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.krcp.2016.04.004","article-title":"Genetic diagnosis of autosomal dominant polycystic kidney disease: linkage analysis versus direct mutation analysis","volume":"35","author":"Lee","year":"2016","journal-title":"Kidney Res. Clin. Pract."},{"key":"10.1016\/j.addr.2020.08.011_bb0250","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0255","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0260","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.08.011_bb0265","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.08.011_bb0275","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1073\/pnas.98.3.1182","article-title":"Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel","volume":"98","author":"Gonz","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0280","doi-asserted-by":"crossref","first-page":"11558","DOI":"10.1073\/pnas.0903684106","article-title":"Structural and molecular basis of the assembly of the TRPP2\/PKD1 complex","volume":"106","author":"Yu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0285","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMra1010172","article-title":"Ciliopathies","volume":"364","author":"Hildebrandt","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0290","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.3390\/s90907003","article-title":"Primary cilia: highly sophisticated biological sensors","volume":"9","author":"Abou Alaiwi","year":"2009","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.addr.2020.08.011_bb0295","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00441-006-0226-0","article-title":"Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD)","volume":"326","author":"Sweeney","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2017.00221","article-title":"Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses","volume":"5","author":"Bergmann","year":"2018","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.addr.2020.08.011_bb0305","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/pr.2013.191","article-title":"Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy","volume":"75","author":"Sweeney","year":"2014","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng833","article-title":"The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein","volume":"30","author":"Ward","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2020.08.011_bb0315","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ng.3871","article-title":"Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease","volume":"49","author":"Lu","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2020.08.011_bb0320","first-page":"69","article-title":"Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"10.1016\/j.addr.2020.08.011_bb0325","first-page":"24","article-title":"Defining the difference: what makes biologics unique","volume":"1","author":"Morrow","year":"2004","journal-title":"Biotechnol. Healthc."},{"key":"10.1016\/j.addr.2020.08.011_bb0330","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.011_bb0335","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.addr.2020.08.011_bb0340","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1073\/pnas.0913667107","article-title":"Paradoxical glomerular filtration of carbon nanotubes","volume":"107","author":"Ruggiero","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0345","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2020.08.011_bb0350","first-page":"73","article-title":"N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity","volume":"13","author":"John","year":"2008","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0355","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0022-3565(25)10472-2","article-title":"Whole body and brain distribution of [3H]cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration","volume":"263","author":"Weber","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2020.08.011_bb0360","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.addr.2020.08.011_bb0365","doi-asserted-by":"crossref","first-page":"327950","DOI":"10.1155\/2014\/327950","article-title":"Next generation delivery system for proteins and genes of therapeutic purpose: why and how?","volume":"2014","author":"Sharma","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0370","first-page":"18.1.1","article-title":"Introduction to peptide synthesis","volume":"69","author":"Fields","year":"2012","journal-title":"Curr. Protoc. Protein Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0375","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/acs.joc.8b03001","article-title":"Sustainability challenges in peptide synthesis and purification: from R&D to production","volume":"84","author":"Isidro-Llobet","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1385\/MB:33:3:239","article-title":"Methods and protocols of modern solid phase peptide synthesis","volume":"33","author":"Amblard","year":"2006","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.011_bb0385","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/molecules24101855","article-title":"Peptide conjugates with small molecules designed to enhance efficacy and safety","volume":"24","author":"He","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2020.08.011_bb0390","series-title":"Peptide Applications in Biomedicine, Biotechnology and Bioengineering","first-page":"1","article-title":"1 - Peptide synthesis: methods, trends, and challenges","author":"Petrou","year":"2018"},{"key":"10.1016\/j.addr.2020.08.011_bb0395","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/biot.201100129","article-title":"Bacterial display in combinatorial protein engineering","volume":"6","author":"L\u00f6fblom","year":"2011","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.addr.2020.08.011_bb0400","doi-asserted-by":"crossref","first-page":"13755","DOI":"10.3390\/molecules190913755","article-title":"Recent advances in chemoenzymatic peptide syntheses","volume":"19","author":"Yazawa","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2020.08.011_bb0405","doi-asserted-by":"crossref","first-page":"F677","DOI":"10.1152\/ajprenal.00119.2017","article-title":"The regulatory 1\u03b1 subunit of protein kinase A modulates renal cystogenesis","volume":"313","author":"Ye","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0415","series-title":"Cell Proliferation and Apoptosis in ADPKD","author":"L. E.J","year":"2016"},{"key":"10.1016\/j.addr.2020.08.011_bb0420","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.kint.2016.10.039","article-title":"STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease","volume":"91","author":"Fragiadaki","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0425","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0430","series-title":"Polycystic Kidney Disease","author":"Li","year":"2015"},{"key":"10.1016\/j.addr.2020.08.011_bb0435","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0440","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.111","article-title":"A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5\u2019 end of Pkd1","volume":"73","author":"Starremans","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0445","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway1","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0450","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway11See Editorial by Grande, p. 1770","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0455","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.ki.5002229","article-title":"Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras\/Raf signalling system","volume":"72","author":"Parker","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0465","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1073\/pnas.93.19.10206","article-title":"Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells","volume":"93","author":"Brill","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0470","first-page":"C389","article-title":"A role for CFTR in human autosomal dominant polycystic kidney disease","volume":"270","author":"Hanaoka","year":"1996","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.addr.2020.08.011_bb0475","doi-asserted-by":"crossref","first-page":"10679","DOI":"10.1073\/pnas.1016214108","article-title":"Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0480","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/j.ajkd.2005.06.017","article-title":"B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy","volume":"46","author":"Vickery","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.addr.2020.08.011_bb0485","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.kint.2017.02.017","article-title":"B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease","volume":"92","author":"Holditch","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0490","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1073\/pnas.1620454114","article-title":"Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease","volume":"114","author":"Ciolek","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0495","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.3390\/ijms21114170","article-title":"Regulatory mechanisms of somatostatin expression","volume":"21","author":"Ampofo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0500","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0505","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1185\/03007990903328959","article-title":"From somatostatin to octreotide LAR: evolution of a somatostatin analogue","volume":"25","author":"Anthony","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2020.08.011_bb0510","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","article-title":"Roles of mTOR complexes in the kidney: implications for renal disease and transplantation","volume":"12","author":"Fantus","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0515","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.addr.2020.08.011_bb0520","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0525","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0530","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2020.08.011_bb0535","first-page":"195","article-title":"Molecular pathways and therapies in autosomal-dominant polycystic kidney disease","volume":"30","author":"Saigusa","year":"2015","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.addr.2020.08.011_bb0540","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0545","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1073\/pnas.1201689109","article-title":"Distinct perturbation of the translatome by the antidiabetic drug metformin","volume":"109","author":"Larsson","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0550","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M210621200","article-title":"Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells","volume":"278","author":"Hallows","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0555","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/15384101.2017.1304735","article-title":"SPAR, a lncRNA encoded mTORC1 inhibitor","volume":"16","author":"Matsumoto","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.addr.2020.08.011_bb0560","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature21034","article-title":"mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide","volume":"541","author":"Matsumoto","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.08.011_bb0565","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1681\/ASN.2013020176","article-title":"Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts","volume":"24","author":"Fan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0570","doi-asserted-by":"crossref","first-page":"a008730","DOI":"10.1101\/cshperspect.a008730","article-title":"Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation","volume":"5","author":"Silke","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0575","first-page":"158","article-title":"Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model","volume":"26","author":"Zhu","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2020.08.011_bb0580","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1681\/ASN.2006121355","article-title":"Wnt signaling in polycystic kidney disease","volume":"18","author":"Benzing","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0585","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1681\/ASN.2008111173","article-title":"Planar cell polarity and the kidney","volume":"20","author":"McNeill","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0590","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B978-0-12-394592-1.00011-9","article-title":"The kidney and planar cell polarity","volume":"101","author":"Carroll","year":"2012","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0595","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng1701","article-title":"Defective planar cell polarity in polycystic kidney disease","volume":"38","author":"Fischer","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2020.08.011_bb0600","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/hmg\/ddn045","article-title":"Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia","volume":"17","author":"Patel","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2020.08.011_bb0605","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1101\/gad.2008011","article-title":"Strange as it may seem: the many links between Wnt signaling, planar cell polarity, and cilia","volume":"25","author":"Wallingford","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2020.08.011_bb0610","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1074\/jbc.M410697200","article-title":"Cystic renal neoplasia following conditional inactivation of Apc in mouse renal tubular epithelium","volume":"280","author":"Qian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0615","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncb1670","article-title":"Kif3a constrains \u03b2-catenin-dependent Wnt signalling through dual ciliary and non-ciliary mechanisms","volume":"10","author":"Corbit","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2017.06.013","article-title":"Cell permeable stapled peptide inhibitor of wnt signaling that targets \u03b2-catenin protein-protein interactions","volume":"24","author":"Dietrich","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0625","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1039\/D0CB00016G","article-title":"Macrocyclic peptides that inhibit Wnt signalling via interaction with Wnt3a","volume":"1","author":"Otero-Ramirez","year":"2020","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0630","doi-asserted-by":"crossref","first-page":"109648","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.addr.2020.08.011_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-21132-3","article-title":"Aberrant regulation of Notch3 signaling pathway in polycystic kidney disease","volume":"8","author":"Idowu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.08.011_bb0640","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/0008-5472.CAN-09-3293","article-title":"Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0645","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1101\/gad.308904","article-title":"Notch3 is required for arterial identity and maturation of vascular smooth muscle cells","volume":"18","author":"Domenga","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2020.08.011_bb0650","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1002\/anie.201412070","article-title":"Structure-based design of inhibitors of protein\u2013protein interactions: mimicking peptide binding epitopes","volume":"54","author":"Pelay-Gimeno","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2020.08.011_bb0655","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/17425247.2011.559457","article-title":"Cell-mediated drug delivery","volume":"8","author":"Batrakova","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2020.08.011_bb0660","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/156720111793663606","article-title":"Receptor mediated tumor targeting: an emerging approach for cancer therapy","volume":"8","author":"Chandana","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2020.08.011_bb0665","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.addr.2010.07.011","article-title":"Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells","volume":"62","author":"Dolman","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.011_bb0670","doi-asserted-by":"crossref","first-page":"F70","DOI":"10.1152\/ajprenal.1997.272.1.F70","article-title":"Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule","volume":"272","author":"Birn","year":"1997","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0675","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","article-title":"Targeted drug delivery via the folate receptor","volume":"41","author":"Sudimack","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.011_bb0680","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nano.2009.09.001","article-title":"Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency","volume":"6","author":"Cu","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2020.08.011_bb0685","doi-asserted-by":"crossref","first-page":"F562","DOI":"10.1152\/ajprenal.2001.280.4.F562","article-title":"Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule","volume":"280","author":"Christensen","year":"2001","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0690","doi-asserted-by":"crossref","first-page":"9725","DOI":"10.1073\/pnas.91.21.9725","article-title":"Complete cloning and sequencing of rat gp330\/\"megalin,\" a distinctive member of the low density lipoprotein receptor gene family","volume":"91","author":"Saito","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.011_bb0695","doi-asserted-by":"crossref","first-page":"F900","DOI":"10.1152\/ajprenal.1996.271.4.F900","article-title":"Megalin\/gp330 mediates uptake of albumin in renal proximal tubule","volume":"271","author":"Cui","year":"1996","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0700","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00259-009-1239-1","article-title":"Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides","volume":"37","author":"Vegt","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.addr.2020.08.011_bb0705","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1046\/j.1523-1755.2000.00314.x","article-title":"Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney","volume":"58","author":"Zhai","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0710","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm778","article-title":"Megalin and cubilin: multifunctional endocytic receptors","volume":"3","author":"Christensen","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0715","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/acs.bioconjchem.6b00057","article-title":"Renal targeting: peptide-based drug delivery to proximal tubule cells","volume":"27","author":"Wischnjow","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0720","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1007\/s12274-018-2100-2","article-title":"Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery","volume":"11","author":"Wang","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2020.08.011_bb0725","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acs.bioconjchem.6b00397","article-title":"Drug conjugation affects pharmacokinetics and specificity of kidney-targeted peptide carriers","volume":"27","author":"Janzer","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10173","article-title":"The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles","author":"Huang","year":"2020","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0740","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-2272-7_3","article-title":"Getting across the cell membrane: an overview for small molecules, peptides, and proteins","volume":"1266","author":"Yang","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.08.011_bb0745","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0750","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/jpet.119.257022","article-title":"In vivo imaging of small molecular weight peptides for targeted renal drug delivery: a study in normal and polycystic kidney diseased mice","volume":"370","author":"Lenhardt","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2020.08.011_bb0755","article-title":"Collagenase-cleavable peptide amphiphile micelles as a novel theranostic strategy in atherosclerosis","volume":"1900196","author":"Chin","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2020.08.011_bb0760","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1021\/acs.molpharmaceut.9b00624","article-title":"Detecting functional and accessible folate receptor expression in cancer and polycystic kidneys","volume":"16","author":"Chu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2020.08.011_bb0765","doi-asserted-by":"crossref","first-page":"F535","DOI":"10.1152\/ajprenal.00242.2018","article-title":"\u201cFirst do no harm\u201d: kidney drug targeting to avoid toxicity in ADPKD","volume":"315","author":"Chung","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0770","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1681\/ASN.2004080711","article-title":"Renal tubular reabsorption of folate mediated by folate binding protein 1","volume":"16","author":"Birn","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0775","doi-asserted-by":"crossref","first-page":"F22","DOI":"10.1152\/ajprenal.00385.2005","article-title":"The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins","volume":"291","author":"Birn","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0780","first-page":"C517","article-title":"Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy","volume":"287","author":"Sandoval","year":"2004","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.addr.2020.08.011_bb0785","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/jcbfm.2014.162","article-title":"Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to mptp-induced dopaminergic toxicity in aged mice","volume":"35","author":"Wu","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.addr.2020.08.011_bb0790","first-page":"C381","article-title":"Novel insights into intestinal and renal folate transport. Focus on \u201cApical membrane targeting and trafficking of the human proton-coupled folate transporter in polarized epithelia\u201d","volume":"294","author":"Collins","year":"2008","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.addr.2020.08.011_bb0795","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jps.20457","article-title":"Folate receptor-mediated drug targeting: from therapeutics to diagnostics","volume":"94","author":"Hilgenbrink","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0800","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0805","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0810","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1681\/ASN.2011070711","article-title":"Folate receptor-targeted antioxidant therapy ameliorates renal ischemia-reperfusion injury","volume":"23","author":"Knight","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0815","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.2015121376","article-title":"Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI","volume":"28","author":"Martin-Sanchez","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0820","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1073\/pnas.83.16.5983","article-title":"Receptor-mediated folate accumulation is regulated by the cellular folate content","volume":"83","author":"Kamen","year":"1986","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2020.08.011_bb0825","doi-asserted-by":"crossref","first-page":"17476","DOI":"10.1074\/jbc.M202063200","article-title":"Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with d-peptides derived from chemokines","volume":"277","author":"Zhou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092152","article-title":"Enhancement of binding affinity of folate to its receptor by peptide conjugation","volume":"20","author":"Dharmatti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2020.08.011_bb0835","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.addr.2020.08.011_bb0840","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0845","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2020.08.011_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1995-705X.132136","article-title":"Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India","volume":"15","author":"Patra","year":"2014","journal-title":"Heart Views"},{"key":"10.1016\/j.addr.2020.08.011_bb0855","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/jcm3041276","article-title":"Review of tolvaptan's pharmacokinetic and pharmacodynamic properties and drug interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0860","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.2013101037","article-title":"Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again","volume":"25","author":"Rinschen","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0865","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"28","author":"Torres","year":"2008","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0870","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040010","article-title":"Vasopressin V2R-targeting peptide carrier mediates siRNA delivery into collecting duct cells","volume":"7","author":"Jung","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.08.011_bb0875","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/jm0105676","article-title":"Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake","volume":"45","author":"Rothbard","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0880","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbadis.2010.10.004","article-title":"Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells","volume":"1812","author":"Zheleznova","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.08.011_bb0885","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2020.08.011_bb0890","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/HYPERTENSIONAHA.108.113860","article-title":"Epidermal growth factor receptor signaling in the kidney","volume":"52","author":"Melenhorst Wynand","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.addr.2020.08.011_bb0895","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: recent advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.addr.2020.08.011_bb0900","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8739473","article-title":"Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage","volume":"2018","author":"Rayego-Mateos","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2020.08.011_bb0905","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI2071","article-title":"Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease","volume":"101","author":"Richards","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2020.08.011_bb0910","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1593\/neo.14182","article-title":"Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts","volume":"16","author":"Ahsan","year":"2014","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.addr.2020.08.011_bb0915","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.addr.2020.08.011_bb0920","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s11255-019-02156-8","article-title":"Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease","volume":"51","author":"Ozkurt","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0925","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2353\/ajpath.2006.060245","article-title":"Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease","volume":"169","author":"Chiu","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2020.08.011_bb0930","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/carcin\/bgh329","article-title":"Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion","volume":"26","author":"Zou","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2020.08.011_bb0935","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.amjhyper.2004.06.020","article-title":"Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population","volume":"17","author":"Kelleher","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.addr.2020.08.011_bb0940","doi-asserted-by":"crossref","first-page":"119643","DOI":"10.1016\/j.biomaterials.2019.119643","article-title":"Renal clearance of polymeric nanoparticles by mimicry of glycan surface of viruses","volume":"230","author":"Wyss","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.08.011_bb0945","doi-asserted-by":"crossref","first-page":"F54","DOI":"10.1152\/ajprenal.00143.2016","article-title":"A kidney-selective biopolymer for targeted drug delivery","volume":"312","author":"Bidwell","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0950","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1681\/ASN.V122308","article-title":"Identification of receptor ligands by screening phage-display peptide libraries ex vivo on microdissected kidney tubules","volume":"12","author":"Odermatt","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2020.08.011_bb0955","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10822-012-9614-6","article-title":"Identification of tissue-specific targeting peptide","volume":"26","author":"Jung","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.addr.2020.08.011_bb0960","doi-asserted-by":"crossref","DOI":"10.1038\/380364a0","article-title":"Organ targeting in vivo using phage display peptide libraries","volume":"380","author":"Pasqualini","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.08.011_bb0965","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.kint.2017.02.017","article-title":"B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease","volume":"92","author":"Holditch","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2020.08.011_bb0970","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/jpet.119.257022","article-title":"In vivo imaging of small molecular weight peptides for targeted renal drug delivery: a study in normal and polycystic kidney diseased mice","volume":"370","author":"Lenhard","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2020.08.011_bb0980","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3565(24)38034-6","article-title":"Specific renal delivery of sugar-modified low-molecular-weight peptides","volume":"288","author":"Suzuki","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2020.08.011_bb0985","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/bc300020f","article-title":"Peptide\u2013drug conjugate linked via a disulfide bond for kidney targeted drug delivery","volume":"23","author":"Geng","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.08.011_bb0990","doi-asserted-by":"crossref","first-page":"F54","DOI":"10.1152\/ajprenal.00143.2016","article-title":"A kidney-selective biopolymer for targeted drug delivery","volume":"312","author":"Bidwell","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.addr.2020.08.011_bb0995","series-title":"Anatomy and Physiology","author":"Gordon Betts","year":"2013"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:57:03Z","timestamp":1759208223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20301228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":197,"alternative-id":["S0169409X20301228"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.08.011","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting and therapeutic peptide-based strategies for polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}